| Literature DB >> 31160157 |
Jun-Xia Cao1, Wei-Jian Gao1, Jia You1, Li-Hua Wu1, Jin-Long Liu1, Zheng-Xu Wang2.
Abstract
Immunotherapy with chimeric antigen receptor T (CAR-T) cells has proved remarkably effective in recently published clinical trials. In this meta-analysis, we performed a systematic review in terms of the clinical response treated with CAR-T cells in acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL) and lymphomas patients. Thirty-eight published clinical studies including 665 patients were eligible for response rate (RR) evaluation. The overall pooled RR of CD19-CAR-T cells was 72% (95% confidence interval: 62-77%). The various clinical parameters were analyzed. RR was 81% in ALL, 68% in lymphoma and 70% in CLL. RR in patients who received interleukin (IL)-2 was 70%, whereas in those who did not receive IL-2, it was 74%. RR was 75% with lymphodepletion and 56% without lymphodepletion. RR with autologous cells was 76% and 57% with allogeneic cells. In conclusion, this meta-analysis showed a high clinical RR of CD19-CAR-T cell-based immunotherapy in patients with refractory B-cell malignancies.Entities:
Keywords: CAR-T; acute lymphocytic leukemia; chronic lymphocytic leukemia; lymphomas; meta-analysis
Mesh：
Substances：
Year: 2019 PMID： 31160157 DOI： 10.1016/j.jcyt.2019.04.005
Source DB: PubMed Journal: Cytotherapy ISSN： 1465-3249 Impact factor: 5.414